Digest Network Come funziona
Network
/
Società
Ca
Non verificato

Candid Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
19/09/2025
Salute
Scienza
Medicina - Varie
Biotecnologia
Eventi
Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/08/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Candid Therapeutics to Participate in Investor and Policy Conferences
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/06/2025
Scienza
Medicina - Varie
Biologia
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Industria
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/01/2025
Mercato del lavoro
Biotecnologia
Salute
Biologia
Farmaceutica
Medicina - Varie
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/12/2024
Scienza
Biologia
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/12/2024
Mercato del lavoro
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/10/2024
Mercato del lavoro
Scienza
Biologia
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/09/2024
Biotecnologia
Farmaceutica
Salute
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
Fonte
Candid Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0